Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

526
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
526
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

589
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
589
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

587
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
587
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

470
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
470
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

619
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
619
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

365
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
365

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Modern Era in Personalized Medicine of Dual Antiplatelet Therapy After Myocardial Revascularization.

Journal of clinical medicine·2026
Same author

Transthoracic echocardiography-the overlooked sentinel for pseudoaneurysm: a case report.

European heart journal. Case reports·2026
Same author

Cardiac amyloidosis with apical myocardial infarction: beyond the cherry on top.

ESC heart failure·2026
Same author

Label-free optical observation of disordered-to-ordered transitions in single intrinsically disordered proteins.

Npj biosensing·2026
Same author

Clinical outcomes following transcatheter aortic valve replacement in patients with concordant versus discordant aortic stenosis.

American heart journal plus : cardiology research and practice·2026
Same author

A Real-World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026

関連する実験動画

Updated: Feb 13, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

オブストラクティブ・ハイパートロフィック・カルジオミオパシーにおけるスクワット

Niloufar Javadi1, Patrycja Galazka1, Matthew Peters1

  • 1Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St Luke's Medical Centers, Aurora Health Care, Milwaukee, Wisconsin, USA.

JACC. Case reports
|February 12, 2026
PubMed
まとめ

迅速なスクワット操作は,阻害性高縮性心筋病変における血液動力学的変化を確認することができます. ベッドサイドのマニュアルは,アスクワットのような,アスクルテーションと共に,この状態の臨床評価を強化します.

キーワード:
ドップラーエコーカルディオグラフィーです.アウスクルテーション (Auscultation) とは左心室の流出管の障害 左心室の流出管の障害阻害性高縮性心筋症候群 阻害性高縮性心筋症候群スクワット スクワット スクワット

さらに関連する動画

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

2.2K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K

関連する実験動画

Last Updated: Feb 13, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K
A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

2.2K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K

科学分野:

  • 心臓病学 心臓病学
  • クリニカル・メディシン 臨床医学

背景:

  • 阻害性高縮性心筋病変 (oHCM) は,ユニークな診断上の課題を提示しています.
  • 聴覚とドップラーエコーカルディオグラフィーは,重要な診断ツールです.

研究 の 目的:

  • 阻害性高縮性心筋症候群の患者における迅速なスクワット操作の血液動力学的効果を記録する.
  • 臨床評価におけるベッドサイドマニュバーの有用性を強調する.

主な方法:

  • 2人の患者 (50歳の男性,33歳の女性) が診断された阻害性多動性心筋病変症の症例研究.
  • オスカルテーションとドップラーエコーカルディオグラフィーを利用しました.
  • Valsalvaのストレート,スタンド,およびプロンプト・スクワット・マニュアルの間でのムームの強度の変化を評価した.

主要な成果:

  • 両方の患者は,バルサルバのストレスを加え,立ち上がった時に強まった静脈の噴出音を発症しました.
  • 最初の患者ではうなり声が消え,第2の患者ではプロンプト・スクワット中にグレードIに低下した.
  • これは,oHCMにおけるプロンプト・スクワットによる血液動力学的効果の確認を初めて証明したものである.

結論:

  • ベッドサイドの操作,特に迅速なひざまずきは,閉塞性多動性心筋症の評価に価値があります.
  • アウスクルテーションを高度な画像技術と統合することで,診断の精度が向上します.